Drug-Receptor Interactions

Drug–receptor interactions are the cornerstone of pharmacodynamics—the study of how drugs produce their biological effects. These interactions describe how drugs bind to specific targets (receptors) in the body to initiate, modify, or block physiological processes. The nature, strength, and consequence of this binding determine a drug’s efficacy, potency, selectivity, and therapeutic profile. Understanding these interactions is crucial for drug discovery, therapeutic use, side effect prediction, and personalized medicine.

This exposition presents a detailed, structured, and professional discussion of drug–receptor interactions, including receptor types, binding principles, signal transduction mechanisms, interaction models, quantitative pharmacological parameters, and implications for clinical practice.

---

1. Definition and Relevance

A drug–receptor interaction is a specific molecular association between a drug (ligand) and a biological macromolecule (receptor), resulting in a conformational change in the receptor that triggers a biological response.

• The receptor is typically a protein—such as a membrane-bound enzyme, ion channel, or nuclear transcription factor.

• The drug (ligand) can be an agonist, antagonist, partial agonist, or inverse agonist.

• The interaction is non-covalent, usually reversible, and based on affinity (binding strength) and intrinsic activity (ability to produce a response).

---

2. Types of Drug Receptors

A. Cell Surface Receptors

• G-Protein-Coupled Receptors (GPCRs)

  • Largest receptor family; involved in neurotransmission, cardiovascular regulation, etc.

  • Example: β2-adrenergic receptor

• Ion Channel-Linked Receptors (Ligand-Gated)

  • Open or close channels for ions such as Na⁺, K⁺, Ca²⁺.

  • Example: Nicotinic acetylcholine receptor

• Enzyme-Linked Receptors (Tyrosine Kinase Receptors)

  • Regulate cell proliferation and differentiation.

  • Example: Insulin receptor

B. Intracellular Receptors

• Located in cytoplasm or nucleus

• Bind lipophilic drugs/hormones that cross the cell membrane

• Act as transcription factors

• Example: Glucocorticoid receptor

C. Enzymes as Receptors

• Drugs may inhibit or activate enzymes

• Example: Aspirin inhibits cyclooxygenase (COX)

D. Transport Proteins

• Control movement of substances across membranes

• Example: SSRIs inhibit serotonin reuptake transporter (SERT)

---

3. Nature of Drug–Receptor Binding

Drug–receptor binding is governed by non-covalent forces:

• Ionic bonds – electrostatic attraction; strong and long-range

• Hydrogen bonds – moderate strength

• Van der Waals forces – weak, transient

• Hydrophobic interactions – important for lipid-soluble drugs

• Covalent bonds (rare) – irreversible; e.g., organophosphates with acetylcholinesterase

The binding site is typically a three-dimensional cavity on the receptor specific to the drug's shape and physicochemical properties.

---

4. Agonists and Antagonists

A. Agonist

• Binds to and activates receptor

• Mimics endogenous ligand

• Has affinity + intrinsic activity

Types:

• Full agonist: Produces maximal response (e.g., morphine)

• Partial agonist: Produces submaximal response even at full receptor occupancy (e.g., buprenorphine)

B. Antagonist

• Binds but does not activate receptor

• Blocks action of agonists

• Has affinity but no intrinsic activity

Types:

• Competitive antagonist: Reversible binding at active site (e.g., naloxone)

• Non-competitive antagonist: Irreversible or allosteric binding

• Functional antagonist: Produces opposing physiological effects

C. Inverse Agonist

• Binds to receptor and reduces its basal activity (e.g., beta-carbolines at GABA-A receptor)

---

5. Receptor Theories and Models

A. Occupancy Theory

• Response is proportional to number of occupied receptors

• Limitation: does not account for partial agonism

B. Two-State Model

• Receptors exist in active (R*) and inactive (R) states

• Agonists stabilize R*, antagonists do not shift the balance

C. Affinity vs. Efficacy

• Affinity: Ability to bind the receptor

• Efficacy (Intrinsic activity): Ability to activate the receptor

---

6. Signal Transduction Pathways

Once a drug binds, the receptor initiates a cascade of intracellular signaling leading to physiological changes.

A. GPCR Pathway

• Activates G-protein → stimulates or inhibits enzymes (e.g., adenylyl cyclase, phospholipase C)

• Secondary messengers (cAMP, IP₃, DAG) trigger downstream effects

B. Ion Channels

• Rapid onset, used in neurotransmission

• Ligand opens ion pore (e.g., Na⁺ influx → depolarization)

C. Enzyme-Linked Receptors

• Binding causes dimerization → autophosphorylation → downstream phosphorylation cascade (e.g., MAPK pathway)

D. Intracellular Receptors

• Ligand–receptor complex translocates to nucleus → binds DNA → alters gene transcription

---

7. Quantitative Parameters in Drug–Receptor Interaction

A. Dose–Response Relationship

• Graded response: Response increases with dose until maximum (E_max)

• Log-dose curve: Sigmoidal, demonstrates potency and efficacy

B. Affinity Constant (Kd)

• Concentration at which 50% of receptors are occupied

• Lower Kd = higher affinity

C. EC₅₀ (Effective Concentration)

• Concentration producing 50% of maximum effect

• Reflects potency

D. IC₅₀ / Ki (Inhibitory constants)

• Used for antagonists or enzyme inhibitors

• IC₅₀: Concentration inhibiting 50% of activity

• Ki: Binding affinity of inhibitor

E. Therapeutic Index (TI)

• Ratio of TD₅₀/ED₅₀

• Higher TI = safer drug

---

8. Desensitization and Tolerance

Prolonged stimulation can lead to:

• Tachyphylaxis: Rapid loss of effect (e.g., nasal decongestants)

• Downregulation: Decreased receptor numbers

• Upregulation: Increased receptor sensitivity after chronic antagonist use (e.g., beta-blockers withdrawal)

---

9. Examples of Drug–Receptor Interactions

Drug	Receptor	Type	Effect
Salbutamol	β2-adrenergic receptor	Full agonist	Bronchodilation
Naloxone	μ-opioid receptor	Antagonist	Reverses opioid overdose
Diazepam	GABA-A receptor	Agonist (modulator)	Sedation, anxiolysis
Tamoxifen	Estrogen receptor	Partial agonist/antagonist	Breast cancer treatment
Propranolol	β-adrenergic receptor	Antagonist	Lowers heart rate and BP
Cetirizine	H1 histamine receptor	Antagonist	Treats allergy symptoms
Morphine	μ-opioid receptor	Full agonist	Analgesia
Buprenorphine	μ-opioid receptor	Partial agonist	Pain management, addiction therapy

10. Clinical Implications of Drug–Receptor Interactions

• Selectivity: High selectivity reduces off-target effects.

• Potency: Determines therapeutic dose.

• Efficacy: Defines clinical outcome.

• Drug design: Understanding receptor binding aids rational drug design.

• Adverse effects: Off-target receptor interactions cause toxicity.

• Pharmacogenetics: Receptor polymorphisms affect individual response (e.g., β2-receptor variants in asthma).

• Drug interactions: Competition at receptor sites can alter drug action